Skip to main content

Table 2 Risk of febrile neutropenia across the cycles

From: Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

Risk of febrile neutropenia

Cycle 1

Cycle 2

Cycle 3+

Risk per cycle with pemetrexed

0.00%

1.55%

1.04%

Risk per cycle with docetaxel

12.11%

2.63%

1.05%

  1. Source: Eli Lilly, data on file, JMEI trial, 2008
  2. The risk per cycle of a patient experiencing FN assuming greatest risk after cycle 1, remaining constant after cycle 3.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us